|
|
Stemina Biomarker Discovery is a metabolomics company focused on the discovery, development and commercialization of molecular biomarkers to improve drug safety and human health. Stemina’s cell based assays arise from the strategic convergence of two cutting edge technologies: human embryonic stem (hES) cells and metabolomics. Stemina uses mass spectrometry to analyze the small molecules secreted by hES cells, and differentiated cells such as heart and neural cells made from hES cells, in response to drugs, injury or disease. Stemina opened its state-of-the-art facilities for hES cell culture and mass spectrometry in the UW Research Park in Madison Wisconsin on November 1, 2007.
Stemina News
-
Stemina and California Stem Cell form Collaboration | 2009-09-17
California Stem Cell and Stemina Biomarker Discovery Announce Collaboration to Validate Effectiveness of Human Embryonic Stem Cell-Derived Cardiomyocyte Progenitors for use in Predictive Toxicology. The impetus behind the CSC and Stemina collaboration was to develop a predictive assay to screen for cardiotoxicity, using a variety of anti-cancer drugs with different and distinct mechanisms of action that are known to induce cardiotoxicity and potentially cardiomyopathy
-
Paul West Presents Webinar | 2009-09-23
Paul West has been invited to present at a Genetic Engineering News & Biotechnology Webinar, “Advances in Compound Identification Using Metabolomics”. The primary focus of Paul’s presentation entitled “De Novo Metabolite Chemical Structure Determination” will be metabolite chemical structure determination using LC-MS, accurate mass and MS-MS. The Webinar will be on September 23, 2009 at 10:00 am PDT, 12:00 pm CDT, 1:00 pm EDT. For more details, click on the link:
-
Stemina launches its first commercial product | 2009-04-29
Madison start-up Stemina Biomarker Discovery Inc. has launched its first commercial product, which uses human embryonic stem cells to screen drugs for their likelihood to cause birth defects. The launch comes shortly after President Barack Obama lifted restrictions on stem cell research, opening up opportunities for companies like Stemina, which also this month launched its second round of financing.
-
Promega and Stemina Biomarker Discovery collaborate to improve techniques in stem cell research | 2009-02-16
Promega Corporation, a provider of innovative solutions and technical support, and Stemina Biomarker Discovery, Inc. announced today that they have entered into a collaborative research agreement. The collaboration will combine Stemina’s expertise in human embryonic stem (hES) cells with Promega’s expertise in biological reagents and related instrumentation for use in studying cellular and functional biology.
-
Dr. Cezar was featured in Forbes Magazine | 2008-06
Dr. Gabriela Gebrin Cezar, Stemina’s Chief Scientific Officer and scientific founder, was featured in the June 2008 issue of Forbes Magazine as a luminary in stem cell science. Dr. Cezar, who is also an Assistant Professor at the University of Wisconsin, is the world expert in human embryonic stem cells and metabolomics.
|
